【Immune checkpoints】NFAT

Product Center > Cell lines > Immune checkpoints

【TAA】TNFRSF8(CD30)

Product Center > Cell lines > TAA

【Antibody function】ADCC

Product Center > Cell lines > Antibody function

【Antibody function】FcγR

Product Center > Cell lines > Antibody function

【Antibody function】Jurkat NFAT

Product Center > Cell lines > Antibody function

【Immunotherapy target】CD3

Product Center > Cell lines > Immunotherapy target

【Immune checkpoints】CD33(SIGLEC3)

Product Center > Cell lines > Immune checkpoints

【Biosimilar Antibodies】TAA

Product Center > Antibodies > Biosimilar Antibodies

【Biosimilar Antibodies】Immunotherapy target

Product Center > Antibodies > Biosimilar Antibodies

【TAA】CD38

Product Center > Cell lines > TAA

【Biosimilar Antibodies】Bispecific Antibody

Product Center > Antibodies > Biosimilar Antibodies

【Insights】CD38: Sarclisa approved in the US as the first anti-CD38 therapy in combination with standard-of-care treatment for adult patients with newly diagnosed multiple myeloma not eligible for transplant

2024-09-23

【Insights】CD19/CD20/CD3：GSK enters agreement to acquire CMG1A46 from Chimagen Bioscience

2024-11-01

【Insights】AstraZeneca Announces Data from First-in-Human Phase 1 Study of AZD0486, a Novel CD19xCD3 T-Cell Activator, in Relapsed/Refractory Diffuse Large B-Cell Lymphoma

2024-11-08

【Product Center】CD3-CD2-tsAb Reporter Jurkat(CD58 KO) Cell Line

Product Center

【Product Center】H_CD3D CD3E KO Jurkat Cell Line

Product Center

【Product Center】ADCC FcγRIIIa(158V) Reporter Jurkat(CD3 KO) Cell Line

Product Center

【Product Center】Mouse_CD3 HEK-293 Cell Line

Product Center

【Product Center】H_CD3 CHO-K1 Cell Line

Product Center

【Product Center】H_TNFRSF8(CD30) MC38 Cell Line

Product Center